Testing a new antibiotic for hospitalized babies with infection
Part of Infections clinical trials.
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is less than 9 months old, including if they were born early (preterm).
- Your baby is currently in the hospital with a suspected or confirmed bacterial infection.
- Your baby needs intravenous (IV) antibiotics for the infection.
- Your baby does not have severe kidney problems or require dialysis.
- If your baby has already received antibiotics for a gram-negative bacteria, it must be for less than 24 hours, or the infection hasn't improved after 48 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
This trial tests a new combination of antibiotics (sulbactam-durlobactam) for children with a serious infection caused by Acinetobacter bacteria. The goal is to see if this treatment is safe and works well for kids.
This trial is checking how well a combination of two antibiotics, aztreonam and avibactam, works in patients who have a specific type of drug-resistant bacterial infection in the belly or lungs. It aims to offer a new treatment option for infections that are hard to cure.
This trial studies a combination antibiotic called aztreonam-avibactam for treating infections caused by hard-to-treat bacteria, especially those that produce certain enzymes (MBLs). It aims to see how well this medicine works in hospital patients.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
Hear when a new Gram-negative Bacterial Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.